La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Coloplast Gestione

Gestione criteri di controllo 4/4

Coloplast's Il CEO è Kristian Villumsen, nominato in Dec2018, e ha un mandato di 5.67 anni. la retribuzione annua totale è DKK 23.30M, composta da 51.5% di stipendio e 48.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.045% delle azioni della società, per un valore di DKK 94.65M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.3 anni e 6.6 anni.

Informazioni chiave

Kristian Villumsen

Amministratore delegato

DKK 23.3m

Compenso totale

Percentuale dello stipendio del CEO	51.5%
Mandato del CEO	5.7yrs
Proprietà del CEO	0.05%
Durata media del management	6.3yrs
Durata media del Consiglio di amministrazione	6.6yrs

Aggiornamenti recenti sulla gestione

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Nov 25

Recent updates

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

Jul 17

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jun 29

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

May 21

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

May 10

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

May 09

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 04

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Nov 16

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Sep 30

Is Coloplast (CPH:COLO B) A Risky Investment?

Jun 28

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Jun 10

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Mar 22

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

Mar 01

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 14

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 26

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Nov 25

Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year

Nov 11

With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case

Oct 25

Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)

Aug 26

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jul 27

Here's Why We Think Coloplast (CPH:COLO B) Is Well Worth Watching

Jul 12

Is There An Opportunity With Coloplast A/S' (CPH:COLO B) 45% Undervaluation?

May 23

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of kr.5.00

May 08

Coloplast (CPH:COLO B) Seems To Use Debt Rather Sparingly

Apr 13

Here's Why I Think Coloplast (CPH:COLO B) Is An Interesting Stock

Mar 29

Coloplast A/S (CPH:COLO B) Shares Could Be 41% Below Their Intrinsic Value Estimate

Feb 12

Coloplast (CPH:COLO B) Could Easily Take On More Debt

Jan 12

Is Now The Time To Put Coloplast (CPH:COLO B) On Your Watchlist?

Dec 28

Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Is Not Excessive At All

Nov 25

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

Oct 31

Here's Why Coloplast (CPH:COLO B) Can Manage Its Debt Responsibly

Oct 02

Do Coloplast's (CPH:COLO B) Earnings Warrant Your Attention?

Sep 16

Does This Valuation Of Coloplast A/S (CPH:COLO B) Imply Investors Are Overpaying?

Aug 02

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Kristian Villumsen rispetto agli utili di Coloplast?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	DKK 5b
Mar 31 2024	n/a	n/a	DKK 5b
Dec 31 2023	n/a	n/a	DKK 5b
Sep 30 2023	DKK 23m	DKK 12m	DKK 5b
Jun 30 2023	n/a	n/a	DKK 5b
Mar 31 2023	n/a	n/a	DKK 5b
Dec 31 2022	n/a	n/a	DKK 5b
Sep 30 2022	DKK 21m	DKK 12m	DKK 5b
Jun 30 2022	n/a	n/a	DKK 5b
Mar 31 2022	n/a	n/a	DKK 5b
Dec 31 2021	n/a	n/a	DKK 5b
Sep 30 2021	DKK 22m	DKK 11m	DKK 5b
Jun 30 2021	n/a	n/a	DKK 5b
Mar 31 2021	n/a	n/a	DKK 4b
Dec 31 2020	n/a	n/a	DKK 4b
Sep 30 2020	DKK 20m	DKK 11m	DKK 4b
Jun 30 2020	n/a	n/a	DKK 4b
Mar 31 2020	n/a	n/a	DKK 4b
Dec 31 2019	n/a	n/a	DKK 4b
Sep 30 2019	DKK 17m	DKK 10m	DKK 4b
Jun 30 2019	n/a	n/a	DKK 4b
Mar 31 2019	n/a	n/a	DKK 4b
Dec 31 2018	n/a	n/a	DKK 4b
Sep 30 2018	DKK 11m	DKK 6m	DKK 4b
Jun 30 2018	n/a	n/a	DKK 4b
Mar 31 2018	n/a	n/a	DKK 4b
Dec 31 2017	n/a	n/a	DKK 4b
Sep 30 2017	DKK 10m	DKK 6m	DKK 4b

Compensazione vs Mercato: La retribuzione totale di Kristian ($USD 3.46M ) è circa la media per le aziende di dimensioni simili nel mercato Danish ($USD 3.69M ).

Compensazione vs guadagni: La retribuzione di Kristian è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Kristian Villumsen (54 yo)

5.7yrs

Mandato

DKK 23,300,000

Compensazione

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Kristian Villumsen	President & CEO	5.7yrs	DKK 23.30m	0.045% DKK 89.9m
Anders Lonning-Skovgaard	Executive VP & CFO	10.1yrs	DKK 11.90m	0.0012% DKK 2.4m
Allan Rasmussen	Executive Vice President of Global Operations	10.1yrs	DKK 10.50m	Nessun dato
Nicolai Andersen	Executive Vice President of Innovation	no data	DKK 10.00m	Nessun dato
Paul Marcun	Executive Vice President of Growth	5.6yrs	DKK 12.00m	Nessun dato
Thomas Barfod	Senior Controller & Employees Representative Director	no data	DKK 450.00k	0.000020% DKK 39.9k
Ellen Bjurgert	Vice President of Investor Relations	7.8yrs	Nessun dato	Nessun dato
Dennis Kaysen	Director of Corporate Communications	no data	Nessun dato	Nessun dato
Dorthe Ronnau	Senior Vice President of People & Culture	2.6yrs	Nessun dato	Nessun dato
Alain Morvan	Senior Vice President of Sales Europe	12.3yrs	Nessun dato	Nessun dato
Rasmus Møller	Senior Vice President of Wound & Skin Care	3.9yrs	Nessun dato	Nessun dato
Manu Varma	Senior Vice President of Chronic Care - North America	6.3yrs	Nessun dato	Nessun dato

6.3yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di COLO B è esperto e expertise (durata media dell'incarico 6.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Thomas Barfod	Senior Controller & Employees Representative Director	18.6yrs	DKK 450.00k	0.000020% DKK 39.9k
Carsten Hellmann	Independent Director	6.7yrs	DKK 690.00k	0.0027% DKK 5.3m
Lars Rasmussen	Chairman of the Board	5.7yrs	DKK 1.84m	0.092% DKK 184.1m
Niels Louis-Hansen	Deputy Chairman	56.6yrs	DKK 938.00k	1.93% DKK 3.8b
Marianne Wiinholt	Independent Director	3.7yrs	DKK 880.00k	0.00022% DKK 439.1k
Jette Nygaard-Andersen	Independent Director	8.7yrs	DKK 600.00k	Nessun dato
Nikolaj Gundersen	Employees Representative Director	6.6yrs	DKK 450.00k	Nessun dato
Roland Pedersen	Employees Representative Director	6.6yrs	DKK 450.00k	0.00072% DKK 1.4m
Annette Bruls	Independent Director	2.7yrs	DKK 600.00k	Nessun dato

6.6yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di COLO B sono considerati esperti (durata media dell'incarico 6.6 anni).

Coloplast Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

President & CEO exercised options and sold kr.13m worth of stock

Deputy Chairman recently bought kr.40m worth of stock

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Less than half of directors are independent

Coloplast Announces Executive Changes

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings: EPS misses analyst expectations

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

First half dividend of kr.5.00 announced

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Second quarter 2024 earnings: EPS misses analyst expectations

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price

Is Coloplast (CPH:COLO B) A Risky Investment?

President & CEO exercised options and sold kr.13m worth of stock

First quarter 2024 earnings: Revenues in line with analyst expectations

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Estimating The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S' (CPH:COLO B) Price Is Out Of Tune With Earnings

Coloplast A/S Approves the Distribution of Year-End Dividend

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Deputy Chairman recently bought kr.40m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

New minor risk - Shareholder dilution

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Is Coloplast (CPH:COLO B) A Risky Investment?

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

First quarter 2023 earnings: EPS misses analyst expectations

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of kr.15.00 per share

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)

Third quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Here's Why We Think Coloplast (CPH:COLO B) Is Well Worth Watching

Is There An Opportunity With Coloplast A/S' (CPH:COLO B) 45% Undervaluation?

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of kr.5.00

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings: Revenues exceed analyst expectations

Less than half of directors are independent

Coloplast (CPH:COLO B) Seems To Use Debt Rather Sparingly

Contraline Names Yelena Tropsha as CTO

Here's Why I Think Coloplast (CPH:COLO B) Is An Interesting Stock

Coloplast A/S (CPH:COLO B) Shares Could Be 41% Below Their Intrinsic Value Estimate

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations